Navigation Links
Evolution of taste receptor may have shaped human sensitivity to toxic compounds

Researchers have found new evidence suggesting that the ability to taste bitter compounds has been strongly advantageous in human evolution.

Animals rely on chemical perception, including the senses of taste and smell, for protection against the harmful compounds found in nature. It is widely believed that behavioral and dietary choices may have reduced the importance of such chemical perception in higher primates, and particularly in humans.

In new work, researchers including Nicole Soranzo of University College London and Bernd Bufe of the German Institute of Human Nutrition have shed light on the potential role natural selection has played in forming our present sensitivities and protecting us from harmful natural chemicals. The research team analyzed the nucleotide sequence of a human gene encoding a bitter-taste receptor that mediates recognition of a class of naturally ubiquitous, but toxic, cyanide-releasing compounds. By analyzing sequences from a large sample of individuals representing 60 human populations, the researchers found evidence that specific variants of the receptor gene have been strongly favored in the early stages of human evolution. Employing additional gene sequence analyses, the authors estimated that the favorably selected versions of the receptor gene arose prior to the expansion of humans out of Africa.

The researchers went on to show experimentally that such variants of the receptor, when expressed in individual cells, conferred an increased sensitivity toward several harmful compounds found in nature.

The work strongly supports a pivotal role for bitter-taste perception in toxin avoidance in humans, an attribute that could have come into particular play during periods of expansion into new environments. More broadly, the work contributes to the debate on the mechanisms governing the evolution of chemical sensory perception and on the role of diet as a selective force in human evolution.


'"/>

Source:Cell Press


Page: 1

Related biology news :

1. To Stop Evolution: New Way Of Fighting Antibiotic Resistance Demonstrated By Scripps Scientists
2. Evolution of life on Earth may hold key to finding life in outer space
3. Evolutionary conservation of a mechanism of longevity from worms to mammals
4. Evolutionary biology research techniques predict cancer
5. Evolutionary shifts in olfactory sensitivities in fruit flies
6. Evolution follows few of the possible paths to antibiotic resistance
7. Evolution mystery: Spider venom and bacteria share same toxin
8. Evolution of irreducible complexity explained
9. Evolutionary scrap-heap challenge: Antifreeze fish make sense out of junk DNA
10. Evolutionary forces explain why women live longer than men
11. Evolution reveals an independent route for diversity in animal form
Post Your Comments:
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... biotechnological company, has presented at the CIC ... (Derio), the first DNA chip concerning diagnosis ... the discrimination between normal, steatosis and NASH ... a progressive disease of the liver of ...
... system is a marvel of versatility, creating a variety of ... To carry out these tasks, immune cells follow a career ... a report in the May 2005 issue of Immunity, Fox ... Ph.D. and Dietmar J. Kappes, Ph.D., show that cell-receptor signaling ...
... of the National Institutes of Health, have built the ... Scientists searching for genes that go awry and cause ... point of reference because it pinpoints which genes are ... normal conditions, without known disease. , Scientists can compare ...
Cached Biology News:Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis 2Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 2Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 3Gov't Creates Gene Database of Normal Human Tissues 2Gov't Creates Gene Database of Normal Human Tissues 3Gov't Creates Gene Database of Normal Human Tissues 4
(Date:12/24/2014)... 23, 2014 Vermillion, Inc. (Nasdaq:   ... disease, announced today that investors including Oracle Investment ... LLC and several Vermillion directors have agreed to ... Vermillion,s common stock and warrants to purchase unregistered ... placement.  Under the terms of ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... GenomeDx Biosciences today announced that a new ... genomic test for prostate cancer, was able to predict ... radical prostatectomy without adjuvant therapy. Although rapid metastasis in ... tumor genomics to identify these men who have a ... advance. The study has been published online by ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... Laboratories, pathologist, Ronald L. Weiss, MD, MBA, FCAP, received ... Pathologists at CAP ,11, the organization,s annual meeting, held ... the award honors members "who have made a broad ... of pathology." (Logo: http://photos.prnewswire.com/prnh/20110915/SF69370LOGO ) ...
... 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiovascular ... Clinilabs, will utilize QTinno®, NewCardio,s automated cardiac safety solution, ... new drug under development for a central nervous system ... one important aspect of the trial. Clinilabs, ...
... 2011 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), ... announced financial results for the third quarter of 2011. For ... net loss of $4.6 million, or $0.10 per share, as ... per share, for the third quarter of 2010. As of ...
Cached Biology Technology:ARUP Laboratories' Pathologist, Ronald L. Weiss, MD, Honored With Lifetime Achievement Award for Contributions to Patient Care and Pathology 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 3Clinilabs will Conduct Phase 1 Trial Using QTinno® 4Clinilabs will Conduct Phase 1 Trial Using QTinno® 5Orexigen® Therapeutics Reports Third Quarter Financial Results 2Orexigen® Therapeutics Reports Third Quarter Financial Results 3Orexigen® Therapeutics Reports Third Quarter Financial Results 4Orexigen® Therapeutics Reports Third Quarter Financial Results 5